Rotavax^TM: Conviently Administered Oral Rotavirus Vaccine to Prevent Gastroenteritis in Infant

Aridis’ clinical candidate is an oral vaccine that prevents gastroenteritis due to rotavirus infection in infants. Rotavax^TM has successfully completed six NIH and Wyeth sponsored Phase 1 and 2 clinical trials with strong safety and efficacy results. Aridis has exclusively licensed this vaccine from the NIH for the North American and European markets with a combined market potential in excess of $1.5B. Rotavax^TM will be delivered in a highly convenient oral, quick-dissolving thin film dosage form (e.g. Listerine breath freshener strip) designed to capture significant market share.

The room temperature stabilization of Rotavax^TM in the thin film format has been demonstrated, which will simplify storage, shipping, and handling requirements. An additional advantage is that Rotavax^TM will require only two doses. A recent third-party marketing survey demonstrated that more than three out of four physicians and other healthcare providers preferred the convenience of Rotavax^TM once it is available.